Related Experiment Video
Updated: Jul 8, 2025

Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies
Published on: September 27, 2024
Successful management of delayed-onset adenosine deaminase deficiency with novel mutation
Figen Çelebi Çelik1, Özgen Soyöz1, Selime Özen Bölük1
1University of Health Sciences, Izmir Faculty of Medicine, Dr. Behcet Uz Pediatric Diseases & Surgery Training & Research Hospital, Department of Pediatric Allergy & Immunology, Izmir, Turkey.
Abstract:
A 4-year-old boy presented with acute-onset autoimmune cytopenia with severe, persistent lymphopenia, autoimmune thyroiditis, elevated IgE and glucose 6-phosphate dehydrogenase enzyme deficiency. In immunologic evaluation, lower T, B and natural killer cells and higher levels of adenosine deaminase (ADA) metabolites were observed. The compound heterozygous novel ADA gene mutations causing ADA deficiency were detected. Successful immunologic and metabolic cure was achieved with enzyme replacement therapy, followed by reduced intensity conditioning hematopoietic stem cell transplantation from a matched unrelated donor. An interesting aspect of this patient is the detection of novel compound heterozygous mutations without consanguinity and a secondary outcome is the recovery of glucose 6-phosphate dehydrogenase deficiency after hematopoietic stem cell transplantation.
Related Concept Videos
Alzheimer's Disease: Treatment
Heart Failure Drugs: Inotropic Agents
Gene Therapy

